Vaccine Info

Fluad Quadrivalent Influenza Vaccine

Authored by
Last reviewed
January 24, 2021

Fluad Quadrivalent Vaccine Description

Fluad consists of an inactivated, quadrivalent influenza virus antigen produced in eggs and an oil-in-water emulsion adjuvant, MF59.

Fluad is the first FDA-approved seasonal flu shot that contains an adjuvant, which is an immune-enhancing ingredient.

On November 24, 2015, the U.S. Food and Drug Administration sent an approval letter authorizing the introduction or delivery of Fluad into interstate commerce. 

The immune-enhancing ingredient in Fluad is an oil derived from squalene. Squalene is a naturally occurring substance found in humans, animals, and plants.

Adults aged 65 and older who have an aging immune system might have a lower immune response to traditional flu vaccines compared to younger adults.

Squalene, the immune-enhancing ingredient, is proven to provide a robust immune response to help adults' immune systems of 65 and older recognize and respond to the flu virus.

For 2020-2021, quadrivalent (four-component) egg-based vaccines are recommended to contain:

A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus (updated)

A/Hong Kong/2671/2019 (H3N2)-like virus (updated)

B/Washington/02/2019 (B/Victoria lineage)-like virus (updated)

B/Phuket/3073/2013-like (Yamagata lineage) virus.

Fluad Quadrivalent Vaccine Indication

Fluad is indicated for adults 65 years of age and older to achieve active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. 

Fluad Quadrivalent Vaccine Dosage

Fluad is administered as an intramuscular injection in adults 65 years of age and older.

Fluad helps protect against the same flu strains as other seasonal flu shots, but it has something they don’t have: an immune-enhancing ingredient that can help provide a robust immune response to the flu in adults 65 and older. 

Fluad Quadrivalent Vaccine Adverse Events

Some adverse events (reported after regular flu vaccines) were reported more frequently after vaccination with FLUAD. During clinical studies, the adverse events were mild to moderate and temporary: pain, redness at the injection site, headache, muscle aches, and malaise.

Fluad Quadrivalent Vaccine News

October 25, 2020 - Fluad on Par With High-Dose Flu Vax in High-Risk Seniors

September 21, 2020 - Seqirus announced the publication of new real-world evidence (RWE) that demonstrated an MF59® adjuvanted, trivalent influenza vaccine (aTIV) was more effective than a standard-dose non-adjuvanted trivalent seasonal vaccine in preventing influenza-related medical office visits and hospitalizations in adults 65 years and older during the 2017/18 U.S. influenza season.

February 24, 2020 - Seqirus Receives FDA Approval for FLUAD QUADRIVALENT for Adults 65 Years and Older

Clinical Trials

No clinical trials found